GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (ASX:PER) » Definitions » Inventories, Finished Goods

Percheron Therapeutics (ASX:PER) Inventories, Finished Goods : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Percheron Therapeutics Inventories, Finished Goods?


Percheron Therapeutics Inventories, Finished Goods Historical Data

The historical data trend for Percheron Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics Inventories, Finished Goods Chart

Percheron Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Percheron Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Percheron Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Percheron Therapeutics (ASX:PER) Business Description

Traded in Other Exchanges
Address
14 Wallace Avenue, Toorak, VIC, AUS, 3142
Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals. The company operates in two segments that have been identified based on its antisense oligonucleotide products as ATL1102 and ATL1103.

Percheron Therapeutics (ASX:PER) Headlines

No Headlines